Senti Biosciences, Inc. (NASDAQ:SNTI) Sees Significant Drop in Short Interest

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a large decline in short interest in January. As of January 15th, there was short interest totalling 63,600 shares, a decline of 38.8% from the December 31st total of 103,900 shares. Based on an average daily trading volume, of 2,230,000 shares, the short-interest ratio is presently 0.0 days. Currently, 2.2% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Chardan Capital reaffirmed a “buy” rating and issued a $10.00 price target on shares of Senti Biosciences in a report on Monday, December 2nd.

Senti Biosciences Price Performance

Shares of SNTI traded down $0.26 during midday trading on Wednesday, hitting $4.26. 9,161 shares of the company traded hands, compared to its average volume of 86,313. The stock has a 50-day moving average of $4.31 and a 200-day moving average of $3.07. Senti Biosciences has a one year low of $1.52 and a one year high of $16.94. The firm has a market cap of $19.55 million, a P/E ratio of -0.27 and a beta of 2.42.

Senti Biosciences Company Profile

Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.